Pfizer Moving Ahead With Polymerase Inhibitors For Hep C As Competitors Fall
This article was originally published in The Pink Sheet Daily
Executive Summary
Activity and tolerability profile of the Phase IIa compound encourage Pfizer to proceed with development.
You may also be interested in...
Gilead Expands Hep C Portfolio With LG Life Sciences Deal
Gilead Sciences is gaining a Phase II pan-caspase inhibitor for hepatitis C through a licensing agreement with LG Life Sciences worth up to $202 million announced Nov. 7
Gilead Expands Hep C Portfolio With LG Life Sciences Deal
Agreement gives Gilead rights to caspase inhibitors for fibrotic disease, including Phase II candidate LB84451 for chronic hepatitis C.
Gilead Expands Hep C Portfolio With LG Life Sciences Deal
Agreement gives Gilead rights to caspase inhibitors for fibrotic disease, including Phase II candidate LB84451 for chronic hepatitis C.